Aurora BioPharma

Aurora BioPharma has completed two clinical trials in genetically reprogrammed CAR T cell therapy in solid tumor, Glioblastoma and Sarcoma. A Phase I/II trial with its CAR T agent AU-101 was completed in 19 Sarcoma (16 Osteosarcoma) patients, that met its endpoint of safety. Aurora also completed a CAR T trial with its agent AU-105 in Glioblastoma that showed safety, with strong signals of ORR and up to double the historic survival benefit.